drugset / Trial / NCT01071005

Pharmacodynamics of Lorelin Depot (Leuprorelin Acetate - Bergamo) Compared to Lupron Depot ® (Leuprorelin Acetate - Abbot)

NCT01071005

Phase 1 Completed 58 enrolled Azidus Brasil
RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to examine, in healthy subjects, the comparative pharmacodynamics of Lorelin Depot (leuprorelin), manufactured by the Chemical Pharmaceutical Laboratory Bergamo Ltda with the product Lupron Depot ® (leuprorelin), manufactured by Abbott Laboratories Ltd, through the strength of biological markers follicle stimulating hormone (FSH), luteinizing hormone (LH) and total testosterone, associated with the activity of the substance. Secondarily be observed safety (tolerability) of subjects in clinical research through the comparison of clinical and laboratory parameters pre-and post-study, and incidence of adverse events.

Timeline

Start
2010-08
Primary completion
2010-10
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Leuprolide Other / unclassified 3.75 mg

Indications

No indication recorded.